• Join
  • Login
  • Contact


FIP makes it a priority to publish the latest developments in pharmacy practice, pharmaceutical sciences, related global news and prominent events. Our multi-media approach to keeping members, partners and peers informed of what is and will be affecting their area of practice or science is key to keeping information flowing through the FIP network.

2020 Handbook of Pharmaceutical Excipients Ninth Edition

Handbook of Pharmaceutical Excipients Ninth Edition

Editors Paul J Sheskey, Bruno C Hancock, Gary P Moss, David J Goldfarb

The Handbook of Pharmaceutical Excipients is internationally recognised as the authoritative source of information on pharmaceutical excipients.

The definitive summary of pharmacopeia specifications and the regulatory status of excipients, providing you with a one stop resource when researching an excipient for use.

All of the 400+ monographs are also thoroughly cross-referenced and indexed to allow their identification by chemical, non-proprietary or trade names.

Changes to this new edition include:

•    Over 420 fully referenced excipient monographs, many including IR, Raman, and NIR spectra
•    13 monographs new to this edition, including several amino acids and hydrated silicon dioxide
•    250 existing monographs reviewed
•    New chapters providing support to the formulator, such as excipient selection for orally inhaled and also injectable formulations

£430.00 / U$606.00    ISBN:  978-0-85711-375-7    Publishing: 18 Oct 2020       Hardback

2020 British National Formulary (BNF 80)

British National Formulary (BNF 80) New Edition
Joint Formulary Committee
Published jointly by BMJ Publishing Group Ltd and Royal Pharmaceutical Society

The British National Formulary is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.
The new edition provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

Extensive content updates in the BNF 80 edition include:

New monographs on:
•    Beovu ® [brolucizumab] for neovascular (wet) age-related macular degeneration
•    Cytotect ® [cytomegalovirus immunoglobulin] for prophylaxis of cytomegalovirus infection in patients taking immunosuppressants, particularly transplant recipients
•    Mayzent ® [siponimod] for multiple sclerosis [secondary progressive, with active disease]
•    Mulpleo ® [lusutrombopag] for thrombocytopenia [in patients with chronic liver disease undergoing invasive procedures]
•    Staladex ® [leuprorelin acetate] for prostate cancer
•    Zalkya ® [dienogest] for endometriosis

MHRA advice on:
•    Etonogestrel (Nexplanon ®) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury and implant migration
•    Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy
•    Ulipristal acetate (Esmya ®): suspension of the licence due to risk of serious liver injury
•    Sodium valproate and Valproic acid: updated Pregnancy Prevention Programme
•    Tofacitinib (Xeljanz ®): new measures to minimise risk of venous thromboembolism and of serious and fatal infections

Dose changes:
•    Glucagon [update to age ranges for hypoglycaemia]
•    Sodium fluoride [updating dosing for prophylaxis of dental caries]

Updated guidance on Pneumococcal vaccine and Yellow fever vaccine in-line with Public Health England recommendations, management of hypertension and management of impetigo.

£59.95/US$85.00    ISBN 978-0-85711-3696    Publishing 25 Aug 2020      Paperback       

2020 British National Formulary for Children 2020-21

British National Formulary for Children 2020-2021 New Edition

Published jointly by the British Medical Association, Royal Pharmaceutical Society, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group.

The BNF for Children is the first choice for concise medicines information for children. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.
The new edition provides up-to-date guidance on prescribing, dispensing, and administering medicines to children, plus legal and professional guidelines.

Recommendations in the BNF for Children have been constructed on the basis of authoritative sources, emerging evidence and best practice guidelines. The content has been carefully validated by a network of paediatric experts and the process is overseen by a paediatric formulary committee. Content updates in the new edition include:

New monographs on:
•    Gilenya ® [fingolimod] for multiple sclerosis
•    Mozobil ® [plerixafor] to mobilise haematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma or solid malignant tumours
•    Renapime ® [cefepime] for bacterial infection

MHRA advice:
•    Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contra-indications in adults and adolescents
Dose changes
•    Epipen ®preparations (adrenaline/epinephrine) [body-weight ranges for children’s dosing updated]
•    Idursulfase [updated age range]
•    Qvar ® (beclometasone dipropionate) [age-range extension]

Update guidance on Rotavirus vaccine: updated guidance in-line with Public Health England recommendations.

Updated guidance on depression and gastro-oesophageal reflux disease.

£59.95/US$85.00    ISBN 978-0-85711-3726    Publishing 25 Aug 2020      Paperback  

2020 Palliative Care Formulary (PCF 7)

Palliative Care Formulary (PCF 7)         New Edition

Edited by Andrew Wilcock, Paul Howard, Sarah Charlesworth

Grounded in clinical practice, this book includes independent information about drugs used in palliative care, highlighting off-label indications or routes, and dealing with the administration of multiple drugs by continuous subcutaneous infusion.

Updates in the new edition:

•    Two new monographs to reflect increasing use in practice, Denosumab and Parecoxib
•    Hepatic chapter fully revised by a multidisciplinary working group
•    Cannabinoids monograph fully updated and including the 2019 NICE guidance
•    Anticoagulants monograph fully updated to include a new table with prescribing guidance for Direct Oral Anticoagulants (DOACs)
•    Opioid antagonists outside the CNS fully updated to reflect the latest products and evidence for use
•    Urinary antimuscarinics, a new combined monograph to reflect the increasing use of other drugs in this category

Palliative Care Formulary (PCF7) provides unrivalled, in-depth and practical guidance on drugs and treatments to help improve quality of life for adult patients facing progressive life-limiting diseases.

£59.95/U$85.00     ISBN 978-0-85711-3689      Published Jul 2020     Paperback

2020 Martindale: The Complete Drug Reference 40th Edition

Martindale: The Complete Drug Reference 40th Edition       New Edition

Edited by Robert Buckingham

The world’s most comprehensive reference source about drugs and medicines

The new edition of Martindale: The Complete Drug Reference, provides you with practical, evidence-based, global guidance, allowing you to quickly understand the characteristics of drugs and their clinical uses.

Over 120 new monographs include:

•  New antibacterials, such as delafloxacin, eravacycline, omadacycline, ozenoxacin, and plazomicin
•  Further antivirals, including drugs active against HIV (bictegravir, dapivirine, doravirine, ibalizumab), smallpox (tecovirimat), cytomegalovirus (letermovir), influenza (baloxavir marboxil), and hepatitis C (glecaprevir, pibrentasvir, voxilaprevir)
•  New treatment options for migraine (erenumab, fremanezumab, galcanezumab), narcolepsy (solriamfetol), hyperkalaemia (sodium zirconium cyclosilicate), postpartum depression (brexanolone), eosinophilic asthma (benralizumab), hypoactive sexual desire disorder (bremelanotide), glaucoma (netarsudil), African trypanosomiasis (fexinidazole), and irritable bowel syndrome (tenapanor)
•  New antidiabetic drugs, including ertugliflozin, evogliptin, semaglutide, and sotagliflozin
•  Further antineoplastics for treating cancers including PARP inhibitors (niraparib, rucaparib, talazoparib), PI3K inhibitors (alpelisib, copanlisib, duvelisib), and CAR-T therapies (axicabtagene ciloleucel, tisagenlecleucel)
•  Novel targeted treatments for retinal dystrophy (voretigene neparvovec), neurotrophic keratitis (cenegermin), paroxysmal nocturnal haemoglobinuria (ravulizumab), hereditary transthyretin amyloidosis (inotersen, patisiran), spinal muscular atrophy (nusinersen), and hereditary angioedema (lanadelumab)

Updated coverage of proprietary preparations in 43 countries including Australia, China, UK, and USA
Martindale: The Complete Drug Reference is a one-stop authoritative, invaluable reference work covering all aspects of drugs and medicines, essential on any bookshelf.

£585.00/US$825.00      ISBN 978-0-85711-3672    Published May 2020      Hardback, 2 Vol   

2020 Stockley's Drug Interactions Twelfth Edition

Stockley's Drug Interactions Twelfth Edition

The world’s most comprehensive and authoritative reference book on drug interactions

Edited by Claire L Preston

Stockley’s Drug Interactions is the world’s most comprehensive and authoritative book on drug interactions. It provides expertly authored advice on managing drug interactions and will quickly and reliably help you decide your best course of action.

Covers interactions between therapeutic drugs, proprietary medicines, herbal medicines, foods, drinks, and drugs of abuse and provides comprehensive details of the clinical evidence for the interactions under discussion, an assessment of their clinical importance, and clear guidance on managing the interaction in practice.

The 12th edition has almost 500 new monographs, with reviews and updates for the existing 4,500 monographs.

Price: £240.00/US$331.00   ISBN 978-0-85711-3474        Published Mar 2019      Hardback    

The FIP Global Pharmaceutical Observatory (GPO) is a worldwide data hub to inform the advocacy work of our members and partners.  

The FIP Atlas is a platform being developed to showcase our members’ needs and priorities (supported by the data from the GPO), allowing us to identify opportunities for developing pharmacy with, for and through our member organisations.  

Latest intelligence and data on the state of pharmacy and pharmaceutical science around the world.  


Last update 10 May 2019

FIP Congresses